CO2024010469A2 - Derivados de pirazinamida - Google Patents
Derivados de pirazinamidaInfo
- Publication number
- CO2024010469A2 CO2024010469A2 CONC2024/0010469A CO2024010469A CO2024010469A2 CO 2024010469 A2 CO2024010469 A2 CO 2024010469A2 CO 2024010469 A CO2024010469 A CO 2024010469A CO 2024010469 A2 CO2024010469 A2 CO 2024010469A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyrazinamide
- derivatives
- compounds
- derived compounds
- plasmodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fuel Cell (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269879P | 2022-03-24 | 2022-03-24 | |
| PCT/IB2023/052827 WO2023180964A1 (en) | 2022-03-24 | 2023-03-22 | Pyrazine amide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024010469A2 true CO2024010469A2 (es) | 2024-08-08 |
Family
ID=85979464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0010469A CO2024010469A2 (es) | 2022-03-24 | 2024-07-31 | Derivados de pirazinamida |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250197376A1 (https=) |
| EP (1) | EP4499631A1 (https=) |
| JP (1) | JP2025509917A (https=) |
| CN (1) | CN118591538A (https=) |
| AU (1) | AU2023240513A1 (https=) |
| CA (2) | CA3181279A1 (https=) |
| CO (1) | CO2024010469A2 (https=) |
| DO (1) | DOP2024000149A (https=) |
| WO (1) | WO2023180964A1 (https=) |
| ZA (1) | ZA202405048B (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009137081A2 (en) * | 2008-05-07 | 2009-11-12 | Massachusetts Institute Of Technology | Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase |
| CN102089278A (zh) * | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
| ES2921576T3 (es) * | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| LT2925757T (lt) * | 2012-11-19 | 2017-12-27 | Novartis Ag | Junginiai ir kompozicijos, skirti parazitinių ligų gydymui |
| WO2016089977A1 (en) * | 2014-12-03 | 2016-06-09 | Celgene Corporation | Substituted indazole compounds, compositions thereof, and methods of treatment therewith |
| CN110023312A (zh) * | 2016-10-13 | 2019-07-16 | 由卫生与公众服务部部长代表的美利坚合众国 | 阻止疟疾寄生虫传播的化合物和方法 |
| WO2018081863A1 (en) * | 2016-11-04 | 2018-05-11 | University Of Wollongong | 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF |
| EP3790878A1 (en) * | 2018-05-11 | 2021-03-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Quinoline compounds and their preparation and use as antimalarial agents |
-
2022
- 2022-11-04 CA CA3181279A patent/CA3181279A1/en active Pending
-
2023
- 2023-03-22 CA CA3251003A patent/CA3251003A1/en active Pending
- 2023-03-22 CN CN202380018582.3A patent/CN118591538A/zh active Pending
- 2023-03-22 US US18/849,215 patent/US20250197376A1/en active Pending
- 2023-03-22 JP JP2024556043A patent/JP2025509917A/ja active Pending
- 2023-03-22 AU AU2023240513A patent/AU2023240513A1/en active Pending
- 2023-03-22 WO PCT/IB2023/052827 patent/WO2023180964A1/en not_active Ceased
- 2023-03-22 EP EP23715945.4A patent/EP4499631A1/en active Pending
-
2024
- 2024-06-27 ZA ZA2024/05048A patent/ZA202405048B/en unknown
- 2024-07-31 DO DO2024000149A patent/DOP2024000149A/es unknown
- 2024-07-31 CO CONC2024/0010469A patent/CO2024010469A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023180964A1 (en) | 2023-09-28 |
| ZA202405048B (en) | 2025-09-25 |
| EP4499631A1 (en) | 2025-02-05 |
| CA3181279A1 (en) | 2023-09-24 |
| CN118591538A (zh) | 2024-09-03 |
| JP2025509917A (ja) | 2025-04-11 |
| US20250197376A1 (en) | 2025-06-19 |
| AU2023240513A1 (en) | 2024-07-18 |
| CA3251003A1 (en) | 2023-09-28 |
| DOP2024000149A (es) | 2024-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| NI201800093A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer | |
| UY39574A (es) | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene | |
| CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
| PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| CR20170367A (es) | Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
| BR112014030473A2 (pt) | novo diazaespirocicloalcano e azaespirocicloalcano | |
| SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
| PE20151495A1 (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
| DOP2014000012A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| MX2023011864A (es) | Inhibidores de dihidroorotato deshidrogenasa deuterados. | |
| MX2024007938A (es) | Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead. | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| ECSP11010807A (es) | Sales de los compuestos del inhibidor de vih | |
| CO2022002993A2 (es) | Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones referencia cruzada a una solicitud relacionada | |
| CO2024009582A2 (es) | Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap/taz tead | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| CL2010001566A1 (es) | Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune. | |
| UY39779A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| UY38455A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
| CL2023003979A1 (es) | Inhibidores de las transglutaminasas | |
| CO2023008475A2 (es) | Inhibidores de enzimas | |
| CO2024010469A2 (es) | Derivados de pirazinamida | |
| MX2025005720A (es) | Inhibidores de la tirosina-cinasa 2 (tyk2) |